EARLY ALZHEIMER'S DISEASE
Clinical trials for EARLY ALZHEIMER'S DISEASE explained in plain language.
Never miss a new study
Get alerted when new EARLY ALZHEIMER'S DISEASE trials appear
Sign up with your email to follow new studies for EARLY ALZHEIMER'S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Diabetes drug semaglutide tested as Alzheimer's treatment in massive trial
Disease control CompletedThis study tested whether oral semaglutide, a drug used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 adults with mild cognitive impairment or mild dementia took either the drug or a placebo for up to 3 years and 4 months. Researchers measured c…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
Could a diabetes pill slow Alzheimer's? major trial results are in
Disease control CompletedThis study tested whether the diabetes drug semaglutide (taken as a pill) can help people with early Alzheimer's disease. About 1,840 participants received either the drug or a placebo for up to 3 years and 4 months. The main goal was to see if semaglutide slows decline in memory…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New pill targets Alzheimer's in gene carriers – early trial shows promise
Disease control CompletedThis study tested an oral drug called ALZ-801 in 84 people with early Alzheimer's who carry the APOE4 gene variant, which raises risk. The goal was to see if the drug affects key Alzheimer's-related proteins in the blood and brain, and to check its safety. Participants took the d…
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE2 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New Alzheimer's drug targets High-Risk gene carriers
Disease control CompletedThis study tested an experimental drug called ALZ-801 in 325 people with early Alzheimer's disease who carry two copies of the APOE4 gene, a strong risk factor. Participants received either the drug or a placebo for about a year. Researchers measured changes in memory, thinking, …
Matched conditions: EARLY ALZHEIMER'S DISEASE
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC